Lipid-lowering drugs: present and future
Hyperlipidemia is one of the most important risk factors for the development atherosclerotic cardiovascular diseases. The review summarizes data on lipoprotein metabolism and discusses methods pharmacological correction of dyslipidemia. Classification presented Lipid-lowering drugs, pharmacodynamics and pharmacokinetic features, indications for use and side effects of individual representatives, issues of their effectiveness and safety are considered. Prospects for the treatment of dyslipidemia are outlined.
Authors
- Natalia O. Selizarova (ORCID: https://orcid.org/0000-0003-4826-2416)
- S. V. Okovityi (ORCID: https://orcid.org/0000-0003-4294-5531)
- N. A. Anisimova (ORCID: https://orcid.org/0000-0002-2620-2976)
- Svetlana M. Napalkova (ORCID: https://orcid.org/0000-0002-9216-8673)
- O. V. Buyuklinskaya (ORCID: https://orcid.org/0000-0002-4453-1079)
- V. Ts. Bolotova (ORCID: https://orcid.org/0000-0001-7559-186X)
Publication Details
- Journal
- Reviews on Clinical Pharmacology and Drug Therapy
- Published
- 2024-12-15
- DOI
- https://doi.org/10.17816/rcf632629
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00